All In Biotech

Drug Trial Radar · NCT07662928

Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study

Epcoritamab in Combination With Dose Adjusted R-EPOCH for High Risk Burkitt Lymphoma (BL) (BEDROCK Study)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

43

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

May 30, 2031

Study completion Apr 30, 2033

Sponsor

Lead sponsor
AIDS Malignancy ConsortiumResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center
First posted
Jun 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well epcoritamab works in combination with the chemotherapy regimen dose adjusted etoposide, prednisone, Oncovin (vincristine), cyclophosphamide, hydroxydaunorubicin-rituximab (DA-EPOCH-R) in treating patients with high risk Burkitt lymphoma. Epcoritamab binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Epcoritamab is a type of bispecific T-cell engager. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving epcoritamab in combination with the DA-EPOCH-R regimen may be an effective treatment for patients with high risk Burkitt lymphoma.

Conditions

  • Adult Burkitt Lymphoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood and CSF

  • Bone Marrow AspirationProcedure

    Undergo bone marrow biopsy/aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy/aspiration

  • Computed TomographyProcedure

    Undergo PET/CT

  • CyclophosphamideDrug

    Given IV

  • DoxorubicinDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • EpcoritamabBiological

    Given SC

  • EtoposideDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • PrednisoneDrug

    Given PO

  • RituximabBiological

    Given IV

  • VincristineDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who complete at least Cycle 3 among 10 participants (Feasibility)Time frame: Up to 3 cycles (one cycles = 21 days)
  2. Overall survivalTime frame: From date of study registration and the date of death from any cause, assessed up to 2 years after completion of study treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.